



Date: 17 June 2026

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India
E-mail: takeover@nse.co.in
Stock Code: NSE – HCG

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India
E-mail: corp.relations@bseindia.com
Stock Code: BSE – 539787

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations).

Pursuant to Regulation 30 of the SEBI Listing Regulations read with sub-para 20 of Para A of Part A of Schedule III thereof, we hereby disclose that the Directorate General of Health Services, Central Drugs Standard Control Organization (Ethics Committee Division) has issued an order dated 12 June 2026 (received on 16 June 2026) addressed to the HCG Central Ethics Committee of HCG Bangalore Institute of Oncology (**KR Unit Ethics Committee**), located at HCG Towers, Tower-I, P. Kalinga Rao Road, Sampangi Ram Nagar Bangalore Bengaluru (Bangalore) Urban Karnataka - 560027 India, which is one of the units of the Company, directing that the KR Unit Ethics Committee shall be suspended from approving or overseeing any new clinical trial or bioavailability/bioequivalence study, for a period of 24 months from the date of receipt of the order. The suspension is addressed to and limited to this KR Unit Ethics Committee and does not extend to any other ethics committees or other operations (including hospital operation and patient care), or any other unit of the Company. The Company is examining the suspension order and the available legal remedies.

In connection with the aforesaid, a statement containing information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024 and Industry Standards on Regulation 30 of the SEBI Listing Regulations is enclosed herewith as “**Annexure A**”.

The aforesaid details may also be accessed on the website of the Company at <https://www.hcgoncology.com/>.

Kindly take this on record and acknowledge receipt of the intimation.

Thanking you,

FOR HEALTHCARE GLOBAL ENTERPRISES LIMITED

Sunu Manuel
Company Secretary & Compliance Officer
Encl: As above

HealthCare Global Enterprises Limited

Reg Off: HCG Towers #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru - 560 027, Karnataka, India
Corp Off: #3, G-Floor, Tower Block, Unity Buildings Complex, Mission Road, Bengaluru - 560 027, Karnataka, India
91 80 4660 7700 | Email-query@hcgel.com | Website - www.hcgoncology.com | CIN: L15200KA1998PLC023489

Ahmedabad | Bengaluru | Bhavnagar | Chennai | Cuttack | Hubballi | Indore | Jaipur | Kalaburagi | Kenya | Kolkata | Mumbai | Nagpur | Nashik | Ongole | Rajkot | Ranchi | Shimoga | Vadodara | Vijayawada | Vizag



Annexure A

Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with Para A of Part A of Schedule III

Sr. No.	Particulars	Details
1.	Name of the Authority	Central Licensing Authority (CLA), Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Government of India acting through the Drugs Controller General (India).
2.	Nature and details of Action(s) taken or order(s) passed	The Central Licensing Authority has <i>inter alia</i> directed the HCG Central Ethics Committee, HCG Bangalore Institute of Oncology (KR Unit Ethics Committee), at HCG Towers, Tower-I, P. Kalinga Rao Road, Sampangi Ram Nagar Bangalore Bengaluru (Bangalore) Urban Karnataka – 560027, India (one of the units of the Company), which is one of the units of the Company, shall be suspended from approving or overseeing any new clinical trial or bioavailability/bioequivalence (BA/BE) study for a period of 24 months from the receipt of the order.
3.	Date of receipt of Suspension Order	16 June 2026
4.	Details of the violations/contraventions committed or alleged to be committed	The suspension order records alleged failures by this KR Unit Ethics Committee under the New Drugs and Clinical Trials Rules, 2019, including <i>inter alia</i> : (i) failure to report Serious Adverse Events (SAEs) to the CLA/CDSCO within prescribed timelines; (ii) failure to report certain SAEs to CDSCO; (iii) failure to furnish details regarding the SAE review sub-committee; (iv) failure to provide evidence of timely intimation of change in Chairperson of committee; (v) failure to submit signed minutes of meetings for the year 2022; (vi) failure to procure ‘no conflict of interest’ disclosures from members of the KR Unit Ethics Committee; and (vii) deficiencies in SAE causality assessments and participant safety oversight.
5.	Impact on financial operations or other activities of the Listed Entity, quantifiable in monetary terms to the extent possible	Based on current assessment, there is no significant impact on financial operations or other activities of the Company. The suspension is addressed to and limited to this KR Unit Ethics Committee and does not extend to any other ethics committees or other operations (including hospital operation and patient care), or any other unit of the Company. The Company is examining the suspension order and the available legal remedies.